In the latest session, G1 Therapeutics Inc (NASDAQ: GTHX) closed at $4.29 up 3.62% from its previous closing price of $4.14. In other words, the price has increased by $+0.1500 from its previous closing price. On the day, 831956 shares were traded.
Ratios:
For a deeper understanding of G1 Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.45 and its Current Ratio is at 3.87. In the meantime, Its Debt-to-Equity ratio is 1.62 whereas as Long-Term Debt/Eq ratio is at 1.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 30, 2023, Upgraded its rating to Neutral and sets its target price to $10 from $7 previously.
On January 03, 2023, Needham reiterated its Buy rating and also upped its target price recommendation from $32 to $31.
JP Morgan Downgraded its Neutral to Underweight on November 04, 2021, whereas the target price for the stock was revised from $20 to $19.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 18 ’24 when Umstead John W. V sold 6,547 shares for $3.02 per share. The transaction valued at 19,752 led to the insider holds 123,896 shares of the business.
Malik Rajesh sold 28,600 shares of GTHX for $132,143 on Feb 12 ’24. The Chief Medical Officer now owns 169,938 shares after completing the transaction at $4.62 per share. On Jan 04 ’24, another insider, MURDOCK TERRY L, who serves as the Chief Operating Officer of the company, sold 721 shares for $2.94 each. As a result, the insider received 2,121 and left with 103,638 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GTHX now has a Market Capitalization of 224.46M and an Enterprise Value of 198.20M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.71 while its Price-to-Book (P/B) ratio in mrq is 6.30. Its current Enterprise Value per Revenue stands at 2.40 whereas that against EBITDA is -5.78.
Stock Price History:
The Beta on a monthly basis for GTHX is 1.72, which has changed by 56.00% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, GTHX has reached a high of $5.00, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is 3.4981, while the 200-Day Moving Average is calculated to be 2.4193.
Shares Statistics:
For the past three months, GTHX has traded an average of 1.46M shares per day and 807.71k over the past ten days. A total of 51.93M shares are outstanding, with a floating share count of 42.49M. Insiders hold about 18.60% of the company’s shares, while institutions hold 24.16% stake in the company. Shares short for GTHX as of Feb 29, 2024 were 2.91M with a Short Ratio of 2.00, compared to 2.61M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.58% and a Short% of Float of 5.63%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.22, while EPS last year was -$0.53. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.19 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.63 and -$0.79 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.45, with 4 analysts recommending between -$0.3 and -$0.65.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $15.26M this quarter.It ranges from a high estimate of $16M to a low estimate of $14.5M. As of the current estimate, G1 Therapeutics Inc’s year-ago sales were $12.95M, an estimated increase of 17.90% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $16.41M, a decrease of -61.30% less than the figure of $17.90% in the same quarter last year. There is a high estimate of $18.05M for the next quarter, whereas the lowest estimate is $15.29M.
A total of 6 analysts have provided revenue estimates for GTHX’s current fiscal year. The highest revenue estimate was $75.04M, while the lowest revenue estimate was $62.13M, resulting in an average revenue estimate of $69.87M. In the same quarter a year ago, actual revenue was $82.51M, down -15.30% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $103.47M in the next fiscal year. The high estimate is $139.32M and the low estimate is $67.9M. The average revenue growth estimate for next year is up 48.10% from the average revenue estimate for this year.
